BioSpace News Archive

Bardoxolone methyl is an experimental, oral, once-a-day activator of Nrf2, a transcription factor that induces molecular pathways involved in resolving inflammation.

Is there a balancing act we need to have for implementing diversity and inclusion policies? Better put, is there such a thing as being too diverse?

Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.

Leading bioengineering company CN Bio has launched a fee for service program providing Human Organ-on-Chip data to scientists studying non-alcoholic steatohepatitis therapeutics.

Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, provides the following clarification

Rho’s Kristin Gabor was honored on November 8 at the Cystic Fibrosis Foundation’s annual “Brewer’s Ball Celebrating Triangle’s Finest” event that took place at The Rickhouse in Durham.

Foster Corporation, a leader in polymer material solutions for the medical and pharmaceutical markets, received Arkema’s Legacy & Innovation Award at the recent K Show in Dusseldorf, Germany.

Ellume Limited is pleased to announce the appointment of Ms Joanne Moss to its Board as an Independent Non-Executive Director and Chair of Audit and Risk, effective immediately.

Brisbane biotech Microba were chosen to participate in international pitching competition, the Falling Walls Venture in Berlin, based on their world-leading work in analysing gut bacteria.

Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging market, announces that further to the announcement of 15 February 2019, the Company has delivered and installed its latest research unit order for a 9820 Xenon Polariser system from the University of British Columbia https://www.ubc.ca/.